Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BridgeBio's QED to develop oncology candidate infigratinib from Novartis

Executive Summary

BridgeBio Pharma, a 2015 start-up, licensed Novartis AG's oncology candidate infigratinib (BGJ398), which BridgeBio will develop through its concurrently formed new subsidiary QED Therapeutics.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies